Global /Sweden /Healthcare /Drug Manufacturers - General /NEWBRY

Newbury Pharmaceuticals AB (publ)

NEWBRY

• STO: NEWBRY • Delayed

1.33SEK -1.1%

0.1414 USD

As of 5 June 2026, Newbury Pharmaceuticals AB (publ) has a market cap of $4.35M USD, ranking #44983 globally and #737 in Sweden. It ranks #3982 in the Healthcare sector, and #1279 in the Drug Manufacturers - General industry.

Global Rank

44983

Country Rank

737

Sector Rank

3982

Industry Rank

1279

Key Stats

Market Cap

$4.35MUSD

40.73M SEK

Enterprise Value

$3.27MUSD

30.66M SEK

Revenue (TTM)

$3.5MUSD

32.78M SEK

EBITDA (TTM)

-$2.45MUSD

-22.98M SEK

Net Income (TTM)

-$3.04MUSD

-28.48M SEK

EBITDA Margin

-70%

Profit Margin

-87%

PS Ratio

1.2

PB Ratio

1.3

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Karl Alexius Tiger Karlsson open_in_new

Employees

Founded

2020

Website

newburypharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.1%	0.4%	35%	28%	-46%	17%	-59%	-76%	-85%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	NEWBRY Newbury Pharmaceuticals AB ISIN: SE0015244884 TV: TradingView: OMXSTO: NEWBRY SA: Stock Analysis: STO: NEWBRY YF: Yahoo Finance: NEWBRY.ST GF: Google Finance: STO: NEWBRY BA: Barron's: NEWBRY MS: Morningstar: XSTO: NEWBRY	1.33 SEK	TV: TradingView: OMXSTO: NEWBRY SA: Stock Analysis: STO: NEWBRY YF: Yahoo Finance: NEWBRY.ST GF: Google Finance: STO: NEWBRY BA: Barron's: NEWBRY MS: Morningstar: XSTO: NEWBRY

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Newbury Pharmaceuticals AB (publ)

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

Similar Companies

Industry: Drug Manufacturers - General (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Swedish Orphan Biovitrum AB (publ) STO: SOBI	$14.88B 139.44B SEK 342K%	152.8	Sweden
Camurus AB (publ) STO: CAMX	$3.35B 31.37B SEK 77K%	42.8	Sweden
BioArctic AB (publ) STO: BIOA-B	$2.93B 27.5B SEK 67K%	26.9	Sweden
Swedencare AB (publ) STO: SECARE	$451.91M 4.24B SEK 10K%	85.9	Sweden
Vicore Pharma Holding AB (publ) STO: VICO	$300.96M 2.82B SEK 7K%	-	Sweden
Hansa Biopharma AB (publ) STO: HNSA	$294.01M 2.76B SEK 7K%	-	Sweden

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 18M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 13M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 8M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 7M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 7M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 6M%	20.5	Switzerland

chevron_leftBack